Loading stock data…
$1.21-0.01 (-0.82%)
Silo Pharma, Inc.
Silo Pharma, Inc. in the Healthcare sector is trading at $1.21 with a market capitalization of $4M. The stock is currently near its 52-week low of $1.10, remaining 74.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $18,026 | $18,026 | $18,025 | $18,025 |
| Gross Profit | $0↑ | -$2,662 | -$2,663 | -$2,662↓ | $16,566 |
| Operating Income | -$928,949↑ | -$1.59M↓ | -$786,524↑ | -$1.15M↑ | -$1.25M |
| Net Income | -$832,829↑ | -$1.65M↓ | -$881,530↑ | -$1.11M↑ | -$1.20M |
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia...